secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRAIL, Inc. (GRAL)
CIK:        0001699031
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001699031-26-000009
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NHS-Galleri trial misses primary endpoint but shows Stage IV reduction; Q4 rev $43.6M
--------------------------------------------------------------------------------

- Primary endpoint of significant Stage III-IV reduction not met; substantial Stage IV reduction observed across 12 deadly cancers.
- Adding Galleri to standard care yielded four-fold higher cancer detection rate and increased Stage I-II detection of deadly cancers.
- Q4 total revenue $43.6M (+14% YoY); US Galleri revenue $41.3M (+31% YoY). Full year revenue $147.2M (+17% YoY).
- Net loss Q4 $99.2M (incl. $34.6M amort.); full year net loss $408.4M (incl. $138.3M amort. and $28M impairment).
- Galleri PMA submitted to FDA; U.S. sales force to expand based on NHS-Galleri and PATHFINDER 2 results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699031/000169903126000009/0001699031-26-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699031/000169903126000009/gral-20260219.htm
  HTML page:      https://secwatch.observer/filing/0001699031-26-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer